BioCentury
ARTICLE | Clinical News

ADL 8-2698: Phase II

November 22, 1999 8:00 AM UTC

In Phase I and II trials involving a total of 118 patients treated with ADL 8-2698, the compound statistically significantly reversed narcotic-induced slowing of upper and lower gut motility and const...